Tag Archive for: Synaffix

Synaffix/Lanza
ADCs

Elevation Oncology Inc licences Synaffix BV’s ADC platform

Elevation Oncology Inc has inked a US$368m license agreement with Lonza subsidiary Synaffix BV under which Synaffix will link Elevation’s HER3 antibody seribantumab to a monomethyl auristatin E (MMAE) toxic payload with broad therapeutic index.

Read more
Biocytogen Co Ltd
ADC

SOTIO partners with Biocytogen to expand ADC pipeline

Czech Sotio Biotech has inked an R&D and licence option agreement with Chinese antibody maker Biocytogen.

Read more
partnership

Hummingbird and Synaffix in $150m ADC deal

Rational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.

Read more